Plain-English translation of NCT07022964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CD5 CAR-T cell therapy, a new type of cancer treatment that uses your own immune cells (or donor immune cells) that have been engineered in the laboratory to recognize and fight T-cell lymphoma. Researchers want to see if the treatment is safe and how well it works, especially when combined with a stem cell transplant. This is an early-stage study involving up to 36 patients.
T-cell lymphomas that come back after standard chemotherapy or don't respond to it are very difficult to treat, and patients often run out of options. This medication aims to offer a new hope by harnessing the power of the immune system to target these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the engineered immune cells (either your own cells or donor cells that have been processed in the laboratory). Depending on your situation, you may also receive a stem cell transplant as part of your treatment plan. You'll be monitored closely for safety in the first 21 days after the cell infusion, and you'll have regular clinic visits and blood tests to track how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China